Verastem reported $14.64M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
AstraZeneca USD 12.61B 225M Mar/2026
Curis USD 1.14M 8.86M Dec/2025
Cytokinetics USD 19.2M 1.44M Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Laboratory Of America USD 1.01B 20.6M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
TG Therapeutics USD 171.41M 16.98M Mar/2026
Verastem USD 14.64M 14.1M Dec/2025